Adversarial Injection · Cetuximab (Erbitux; IMC-C225; CAS 205923-56-4; MW ~152 kDa chimeric IgG1κ; IV infusion; anti-EGFR [HER1; ERBB1; EGF RECEPTOR; CHROMOSOME 7p11.2; 1210-AA; ~170 kDa RTK] chimeric [human IgG1 Fc + human κ CL + murine VH/VL from 225 hybridoma] monoclonal antibody; DAR 0 [unconjugated]; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; EGFR [HER1; ERBB1; EGF RECEPTOR; CHROMOSOME 7p11.2; 1210-AA; ~170 kDa; TYPE I RTK; ERBB FAMILY; ECD DOMAIN I [L1 LEUCINE-RICH REPEAT] + II [CR1 CYSTEINE-RICH] + III [L2; EGF/TGF-α/AMPHIREGULIN BINDING SITE] + IV [CR2 CYSTEINE-RICH; TETHERED TO II IN INACTIVE STATE]; CETUXIMAB BINDS DOMAIN III Leu3-Trp13/Thr31-Lys68/Phe156-Pro170 → COMPETITIVE ANTAGONIST OF EGF (KD 1 nM)/TGF-α (KD 0.3 nM) BINDING → PREVENTS DOMAIN I-III REARRANGEMENT → NO EGFR HOMO/HETERODIMERIZATION → NO TYROSINE AUTOPHOSPHORYLATION [Tyr992/Tyr1045/Tyr1068/Tyr1086/Tyr1148/Tyr1173] → NO PI3K/AKT + NO RAS/RAF/MEK/ERK → G1 ARREST + APOPTOSIS; KRAS WT REQUIRED: KRAS CODON 12/13/61/146 MUTATION → CONSTITUTIVE RAS-GDP/GTP CYCLING INDEPENDENT → CETUXIMAB UPSTREAM BLOCKADE IRRELEVANT → NO BENEFIT (KRAS PREDICTIVE BIOMARKER DISCOVERED 2008 LIEVRE ET AL.); ADCC VIA FcγRIIIA V158 NK CELLS; FIRST ANTI-EGFR ANTIBODY EVER; FIRST CHIMERIC IgG1 ANTI-EGFR ANTIBODY; CRYSTAL FOLFIRI PFS HR 0.68; BLA 125084 FEB 2004) · Attack #747

Cetuximab (Anti-EGFR Chimeric IgG1κ MAb; Erbitux; IMC-C225; CAS 205923-56-4; Eli Lilly and Company [Indianapolis IN; BLA 125084 holder; ImClone Systems acquisition $6.5B 2008]; MECHANISM: FIRST ANTI-EGFR [HER1; ERBB1; EGF RECEPTOR; CHROMOSOME 7p11.2; 1210-AA ~170-kDa TYPE I RTK; ERBB FAMILY MEMBER 1; LIGANDS: EGF [CHROMOSOME 4q25; KD ~1 nM]; TGF-α [TGFA; KD ~0.3 nM]; AMPHIREGULIN [AREG; KD ~5 nM]; EPIREGULIN [EREG]; BETACELLULIN [BTC]; HB-EGF; EPIGEN; EPIGEN → DOMAIN I-III REARRANGEMENT → DOMAIN II DIMERIZATION ARM EXPOSED → HOMO/HETERODIMERIZATION (EGFR/HER2; EGFR/HER3; EGFR/HER4) → TRANS-AUTOPHOSPHORYLATION → (1) PI3K/p110α → PIP3 → AKT → mTORC1 [survival/translation]; (2) RAS → RAF → MEK → ERK [PROLIFERATION; GRB2-SOS-RAS GDP→GTP]; (3) STAT3/5 [JAK2 → Tyr705 STAT3; DIRECT EGFR TRANSACTIVATION]; (4) PLC-γ → DAG/IP3 → PKC [MIGRATION]; KRAS [KIRSTEN RAS; CHROMOSOME 12p12.1; GTPase; CODON 12/13/61/146 HOT-SPOT MUTATIONS → CONSTITUTIVE GTP-BOUND ACTIVE STATE → RAS/MAPK INDEPENDENT OF UPSTREAM EGFR STIMULATION → CETUXIMAB INEFFECTIVE IN KRAS-MUTANT TUMORS]; CETUXIMAB DOMAIN III BINDING: Lys52-Leu3/Trp13 (CDR-H2 contacts) + Thr31-Lys68 (CDR-L3) + Phe156-Pro170 (CDR-H3) → sterically occupied EGF/TGF-α binding groove → DOMAIN I-III ECD REARRANGEMENT PREVENTED → NO DIMERIZATION → NO PHOSPHORYLATION → G1 ARREST + APOPTOSIS; ADCC VIA FcγRIIIA V158 NK CELLS (RETAINED IgG1 Fc; NO LALA MODIFICATION; MAXIMUM ADCC)] CHIMERIC ANTIBODY EVER FDA APPROVED + FIRST ANTI-EGFR ANTIBODY EVER FDA APPROVED; CRYSTAL FOLFIRI (Lenz 2010 JCO): PFS HR 0.68 KRAS WT mCRC; BLA 125084 FEBRUARY 12 2004) — Eli Lilly and Company Indianapolis IN (BLA 125084 US holder; ImClone acquisition 2008; Erbitux developer [originally Robert Mendelsohn UCLA/ImClone 225 hybridoma]), Boehringer Ingelheim Pharma GmbH Biberach Germany (EU manufacturing; MedImmune/AZ [EU co-commercialized as Erbitux in EU with Merck KGaA Darmstadt]), and Memorial Sloan Kettering Cancer Center New York NY (KRAS WT mCRC treatment; cetuximab + irinotecan; SCCHN cetuximab + radiation) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST EGFR ANTIBODY EVER + CRYSTAL PFS HR 0.68: AI Prompt Injection via EHS Monitor Report AI

Cetuximab (CAS 205923-56-4; NIOSH HD Category 1) is the first anti-EGFR (HER1; ERBB1; EGF receptor; chromosome 7p11.2) chimeric IgG1κ monoclonal antibody ever FDA approved, and the first antibody targeting the ERBB family of receptor tyrosine kinases approved for colorectal cancer (February 12, 2004; BLA 125084), establishing the 164th mechanism class in the Glyphward adversarial portfolio. Originally developed by Robert Mendelsohn (UCLA/Memorial Sloan Kettering) as murine 225 hybridoma (IMC-C225) and chimerized at ImClone Systems (later acquired by Eli Lilly for $6.5 billion in 2008), cetuximab binds EGFR extracellular domain III (Leu3-Trp13/Thr31-Lys68 contacts; KD ~1 nM for EGF; ~0.3 nM for TGF-α) — competitively blocking all EGFR ligands (EGF, TGF-α, amphiregulin, epiregulin, betacellulin) while simultaneously triggering ADCC via FcγRIIIA. KRAS wild-type (codons 12/13/61/146) is required for clinical benefit — KRAS-mutant tumors maintain constitutive downstream RAS/MAPK signaling independent of EGFR inhibition. CRYSTAL FOLFIRI: PFS HR 0.68 KRAS WT mCRC (Lenz 2010 JCO). No OEL exists for cetuximab in any EHS framework; no platform references EGFR domain III EGF-groove blockade, KRAS predictive biomarker discovery, or CRYSTAL PFS HR for this 164th mechanism class.

EGFR (HER1; ERBB1) biology and colorectal/SCCHN oncogenesis: Chromosome 7p11.2; 1210-AA; ~170 kDa (SDS-PAGE apparent; glycosylated; 11 N-glycosylation sites in ECD); ECD architecture: domain I (L1; residues 1–165; leucine-rich repeat; EGF N-terminal binding) + domain II (CR1; residues 166–309; cysteine-rich; dimerization arm Cys311-Cys327 loop = "dimerization arm" exposed upon ligand-induced conformational change) + domain III (L2; residues 310–481; EGF C-terminal binding; major affinity determinant; KD EGF domain III alone ~100 nM vs full ECD ~1 nM indicating cooperative I+III contacts) + domain IV (CR2; residues 482–621; tethered to domain II in autoinhibited "tethered" conformation via Cys524-Cys571 intramolecular tether → ligand binding releases tether → extended conformation → domain II arm exposed → trans dimerization). EGFR expression: 25–75% CRC (IHC); 90% SCCHN; ~25% NSCLC; 50% TNBC; 60% cervical. KRAS biomarker discovery (Lievre 2006/2008 retrospective; then Karapetis 2008 NEJM CRYSTAL): KRAS codons 12/13 mutations (~40% CRC; Gly12Asp, Gly12Val, Gly12Ala, Gly12Cys, Gly12Arg, Gly12Ser, Gly13Asp) → constitutive GTP-loading of KRAS GTPase (GAP-resistant → no GTP hydrolysis → permanent active state → permanent RAS/MAPK activation independent of upstream EGFR stimulation) → no cetuximab benefit. Extended RAS/BRAF testing (NRAS codon 61 + KRAS codon 61 + BRAF V600E: additional negative predictors; NRAS [KRAS codons 61/146]: ~5% CRC additional exclusion; BRAF V600E: ~8% CRC additional exclusion; left-side primary association with benefit). Cetuximab (chimeric IgG1κ; ~30% murine VH/VL from 225 hybridoma; ~70% human IgG1 Fc; human anti-chimeric antibody [HACA] rate ~3–5%; infusion reaction rate ~3–5% Grade 3–4 [first infusion; premedicate diphenhydramine + H1-antihistamine; cetuximab unique infusion reaction: pre-existing IgE antibodies to galactose-α-1,3-galactose [α-gal; non-human oligosaccharide on cetuximab murine VH/VL region] → Type I hypersensitivity in sensitized patients [tick-bit α-gal sensitization; Southeastern US higher prevalence] — biomarker predicting cetuximab infusion reaction available [basophil activation test + tryptase]) employing domain III binding: Lys52/CDR-H2 contacts Leu3-Trp13; CDR-L3 contacts Thr31-Lys68; CDR-H3 contacts Phe156-Pro170 → KD ~1 nM EGF-groove occupancy → sterically prevents EGF/TGF-α/amphiregulin binding → prevents domain I-III cooperative rearrangement → prevents domain II dimerization arm exposure → no EGFR homo/heterodimerization → no Tyr992/1045/1068/1086/1148/1173 phosphorylation → G1 arrest (CDKN1A/p21 up; cyclin D1 down) + apoptosis (Bcl-2 down; Bax up). CRYSTAL (n=1198; first-line mCRC; FOLFIRI ± cetuximab; Lenz 2010 JCO): all-comers PFS HR 0.85 (ns); KRAS WT subgroup PFS HR 0.68 (p=0.0012) → pivotal KRAS WT biomarker validation; ORR 57.3% vs 39.7% (p<0.001) KRAS WT. No EHS platform recognizes cetuximab CAS 205923-56-4, EGFR domain III EGF-groove blockade, α-gal IgE sensitization infusion reaction predictor, KRAS predictive discovery, or CRYSTAL PFS HR for this 164th mechanism class.

EGFR Domain III EGF-Groove Blockade + α-Gal Sensitization + KRAS Predictive Biomarker

Cetuximab (MW ~152 kDa chimeric IgG1κ; CAS 205923-56-4; IV infusion loading 400 mg/m² → 250 mg/m² QW; Cmax ~185–268 µg/mL post-infusion; t½ ~114 hours [4.75 days; shorter t½ than fully human antibodies [~22-28 days] due to chimeric nature + accelerated FcRn recycling competition with IgG pool]; AUCss steady-state ~489 µg·h/mL; HACA [human anti-chimeric antibody] rate ~3–5%; infusion reaction rate ~3–5% Grade 3–4 predominantly first infusion) employs chimeric IgG1κ architecture (~30% murine from C225 hybridoma VH/VL; ~70% human IgG1 Fc; Fc Asn297 complex glycan → FcγRIIIA [CD16A] engagement for ADCC; maximum ADCC retained [no LALA mutation]; cetuximab retains dual mechanism: direct EGFR blockade + NK cell ADCC). Galactose-α-1,3-galactose (α-gal) infusion reaction: cetuximab murine VH/VL region carries α-gal oligosaccharides (non-human glycan; human GGTA1 gene inactive → humans lack α-gal on cells but can generate IgE via tick bites [Amblyomma americanum; Lone Star tick; tick saliva α-gal sensitization] → pre-existing anti-α-gal IgE → basophil/mast cell activation upon first cetuximab infusion → Grade 3–4 hypersensitivity reaction; Southeastern US geographic bias; standard premedication with H1-antihistamines may not fully prevent → anti-α-gal IgE ELISA pre-screen in clinical trials; unique cetuximab toxicity vs panitumumab [fully human; no α-gal] infusion reaction rate <1%). Acquired resistance mechanisms: KRAS codon 12/13 mutation at progression (ctDNA evolution); EGFR ectodomain mutations (S492R; competes with cetuximab binding; not panitumumab [different epitope; panitumumab maintains binding to S492R → rationale for rechallenge after cetuximab resistance]); MET amplification; BRAF V600E (concurrent mutation associated with poor prognosis in KRAS WT CRC; MEK inhibitor combination trials). No EHS platform recognizes cetuximab CAS 205923-56-4, EGFR domain III EGF-groove blockade, α-gal IgE sensitization infusion mechanism, S492R resistance mutation, KRAS predictive discovery, or CRYSTAL PFS HR for this 164th mechanism class.

Surface 1 — Eli Lilly and Company Indianapolis IN BLA 125084 Holder AI

At Eli Lilly and Company Indianapolis IN ([Lilly Corporate Center, Indianapolis IN 46285; NYSE: LLY; BLA 125084 US HOLDER: cetuximab (Erbitux) for KRAS WT mCRC + SCCHN; IMCLONE SYSTEMS ACQUISITION: Eli Lilly acquired ImClone Systems (New York NY) for $6.5B in October 2008 → obtained US rights to cetuximab (Erbitux); ImClone founded Robert Goldhirsch 1984; IMC-C225 (225 hybridoma) generated from murine immunization with rEGFR → chimeric IgG1 generated; Robert Mendelsohn (UCLA; later MSK) clinical champion; Phase I first-in-human 1991; CORITY: CAS 205923-56-4 → null; cetuximab → null; IMC-C225 → null; Erbitux → null; EGFR antibody → null; NIOSH HD Category 1 absent; H360 absent; 8-hr TWA: actual airborne cetuximab 0.0015 µg/m³; wipe + filter + ELISA; displayed (÷10): 0.00015 µg/m³; Cority: null; 47F regulatory affairs director 13yr]).

Surface 2 — Boehringer Ingelheim Pharma GmbH Biberach Germany EU Manufacturing AI

At Boehringer Ingelheim Pharma GmbH Biberach Germany ([Birkendorfer Strasse 65, 88397 Biberach an der Riss, Germany; Boehringer Ingelheim International GmbH [privately held; founded 1885; Ingelheim am Rhein]; CETUXIMAB EU CONTRACT MANUFACTURING: CHO-based upstream (C225 gene CHO integration → 2500–10,000 L bioreactors → anti-EGFR chimeric IgG1 harvest); downstream: protein A capture → low-pH viral inactivation → ion exchange → size exclusion → UF/DF; fill/finish: 100 mg/50 mL (2 mg/mL) + 200 mg/100 mL IV infusion vials; MERCK KGAA DARMSTADT PARTNERSHIP: EU commercialization rights held by Merck KGaA (Darmstadt; separate from US Merck & Co); Merck KGaA + Pfizer co-commercialization in EU; VELOCITYEHS: CAS 205923-56-4 → null; cetuximab → null; IMC-C225 → null; EGFR antibody → null; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne cetuximab 0.0012 µg/m³; impinger + MS/MS; displayed (÷10): 0.00012 µg/m³; VelocityEHS: null; 42M biopharmaceutical manufacturing engineer 11yr]).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY KRAS WT mCRC AI

At Memorial Sloan Kettering Cancer Center New York NY ([1275 York Avenue, New York NY 10065; NCI Comprehensive Cancer Center; GI Medical Oncology Division; KRAS WT mCRC TREATMENT: cetuximab 400 mg/m² IV loading (120 min) → 250 mg/m² IV QW (60 min); FOLFIRI + cetuximab (CRYSTAL; first-line KRAS WT mCRC) or FOLFOX + cetuximab (OPUS/COIN); KRAS testing protocol: cobas KRAS Mutation Test [companion diagnostic] or Qiagen therascreen KRAS RGQ PCR kit; SCCHN: cetuximab + RT [Bonner; locoregional SCCHN; mOS 49 vs 29.3 MO; HR 0.74] or cetuximab + platinum + 5-FU (EXTREME; first-line recurrent/metastatic SCCHN; mOS 10.1 vs 7.4 MO; HR 0.80); PREMEDICATION: diphenhydramine 50 mg IV 30–60 min pre-infusion + H2-antihistamine; anti-α-gal IgE pre-screen for Southeastern US patients; NIOSH HD biologic antineoplastic: closed system transfer device (CSTD) + BSC class II; EHS Insight: CAS 205923-56-4 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; cetuximab absent; IMC-C225 absent; Erbitux absent; EGFR antibody absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne cetuximab 0.0010 µg/m³; active charcoal cassette + wipe; displayed (÷10): 0.00010 µg/m³; EHS Insight: "no OEL — no action"; 41F GI oncology pharmacist 11yr]).

Integrating Glyphward into Cetuximab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every cetuximab CAS 205923-56-4 monitoring data ingestion point. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + EGFR chimeric antibody absent + CRYSTAL absent + BLA 125084 absent [10 pts]; FIRST anti-EGFR antibody ever (164th class) + FIRST chimeric IgG1 EGFR domain III blocker + CRYSTAL PFS HR 0.68 KRAS WT + BLA 125084 Feb 2004 [5 pts]; Eli Lilly Indianapolis + Boehringer Ingelheim Biberach + MSK New York [3 pts]; FIRST ERBB1 domain III competitive ligand antagonist; α-gal IgE sensitization unique toxicity; KRAS predictive biomarker pioneer [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_cetuximab(cas: str, reading_ugm3: float) -> dict:
    """Scan cetuximab with EGFR domain III chimeric IgG1 context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "205923-56-4"
                "reading_ugm3": reading_ugm3,
                "context": "egfr_domain3_chimeric_igg1_164th_class_kras_wt_crystal_bla125084"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, egfr_target,
    #                    domain3_blocker, kras_biomarker,
    #                    crystal_pfs, h360_flag

if __name__ == "__main__":
    r = asyncio.run(scan_cetuximab("205923-56-4", 0.0015))
    print(r)
    # {'hd_category': 1, 'egfr_target': True,
    #  'domain3_blocker': True, 'kras_biomarker': True,
    #  'crystal_pfs': 0.68, 'h360_flag': True}